Hyd based CSIR-IICT develops synthesis of agonist molecule for use in COVAXIN

`COVAXIN', developed by BBIL, is a highly purified and whole virion that inactivates SARS-CoV2. The vaccine is formulated with Algel-IMDG, which contains chemisorbed TLR7/8 agonist onto aluminum hydroxide gel to generate the requisite type of immune responses.

Owing to the significant role played by TLR7/8 agonist molecule in the performance of a vaccine, Council of Scientific and Industrial Research (CSIR) constituent lab, Indian Institute of Chemical Technology (IICT) based in Hyderabad, was approached by BBIL to develop the synthetic route for the agonist molecule with indigenous chemicals at an affordable price and with highest purity. This agonist molecule has aided BBIL to scale up the production of the adjuvant.

The project, spearheaded by Dr. Chandrasekhar, Director and Dr. Raji Reddy, a Senior Scientist from IICT, has been completed in 4 months. Also, the CSIR-IICT team lead by Dr. Mohana Krishna Mudiam, Senior Principal Scientist and Professor (AcCSIR) played a key role in the development of an analytical method for testing TLR7/8 agonist molecule and its method validation procedures through NABL accredited lab.

Acknowledging the work undertaken by CSIR-IICT towards the development of the novel agonist, Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech said: "The process technology developed by CSIR-IICT for the agonist molecule is playing an important role in the production of adjuvant for COVAXIN™."

The unforeseen COVID-19 pandemic has brought along several challenges to the healthcare sector and many Council of Scientific and Industrial Research (CSIR) constituent laboratories have been working relentlessly in partnership with industry to launch repurposed drugs through process development and conducting clinical trials.

CSIR labs have also extensively contributed towards the launching of diagnostic kits including Feluda and Dry Swab Direct RT-PCR method for the screening of SARS-CoV-2.